With more than 1.5 million people now using weight-loss drugs in the UK, the number-crunchers say that actuarial calculations ...

"This is a real concern for all patients who have been benefiting from this medicine. There will be panic and hysteria out ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Medical experts have warned Britons not to turn to fake weight loss jabs after fears the Mounjaro price hike could make it ...

This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price ...

Lyft's co-founders Logan Green and John Zimmer are stepping down from their roles as chair and vice chair of the board of directors. Soros, Appaloosa boost their Nvidia stake. They also bought this ...